Target intelligence / Profile preview

Allergen-directed immune response

Molecular classification
Other
01

Overview

The allergen-directed immune response is a complex physiological process characterized by the immune system's hypersensitivity to environmental allergens. This response is primarily driven by the Type I hypersensitivity pathway, where B cells produce allergen-specific Immunoglobulin E (IgE) that binds to high-affinity FcεRI receptors on mast cells and basophils (Galli et al., 2008, Nature). Upon subsequent exposure, allergen cross-linking of these IgE molecules triggers the release of inflammatory mediators like histamine and leukotrienes, as well as Th2 cytokines such as IL-4, IL-5, and IL-13 (Gould & Sutton, 2008, Nature Reviews Immunology). These mediators lead to the clinical symptoms of allergic diseases, including asthma, allergic rhinitis, and atopic dermatitis (Pawankar et al., 2011, WAO White Book on Allergy). Therapeutic strategies targeting this response include monoclonal antibodies that neutralize IgE or inhibit cytokine signaling, as well as allergen-specific immunotherapy (AIT) designed to shift the immune profile toward tolerance (Akdis & Akdis, 2014, Nature Reviews Drug Discovery). Monitoring this response often involves measuring specific IgE levels and eosinophil counts to assess disease severity and treatment efficacy (Holgate, 2012, Nature Medicine). Safety concerns primarily involve the risk of anaphylaxis during allergen exposure or immunotherapy.

Other names
Allergen-specific immune responseType I hypersensitivityIgE-mediated allergic responseAllergic cascadeAllergen-induced immune response
02

Mechanism of action

Modulation of the allergic cascade through several pathways: sequestration of free IgE to prevent mast cell sensitization, blockade of Th2-promoting cytokines (IL-4, IL-5, IL-13) or their receptors to reduce eosinophilia and airway hyperresponsiveness, and the induction of immune tolerance via allergen-specific immunotherapy (AIT), which promotes the production of IgG4 blocking antibodies and regulatory T cells (Akdis & Akdis, 2014, Nature Reviews Drug Discovery; Galli et al., 2008, Nature).

03

Biological functions

Immune responseInflammationCytokine productionCellular degranulation
04

Disease associations

AllergyAsthmaAllergic rhinitisAtopic dermatitisAnaphylaxis
05

Safety considerations

AnaphylaxisSystemic allergic reactionsInjection site reactionsEosinophilic esophagitis (associated with oral immunotherapy)Oropharyngeal reactions
06

Interacting drugs

Omalizumab

8 more in the full profile.

07

Biomarkers

Allergen-specific IgE (sIgE)Total IgEAllergen-specific IgG4Blood eosinophil countFractional exhaled nitric oxide (FeNO)

Beyond the preview

Go deeper on Allergen-directed immune response.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Allergen-directed immune response.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call